| Table 2. Descriptive analysis of laboratory and clinical outcomes for the first ICSI cycle with the GnRH agonist regimen and the following ICSI cycle with the GnRH antagonist regime | |||
| GnRH Agonist | GnRH Antagonist | p | |
| Laboratory outcomes | |||
| Fertilization rate (%) | 80.31 | 79.72 | 0.262 |
| Embryos obtained (n) | 5.78±0.24 | 6.05±0.25 | 0.432 |
| Embryos transferred (n) | 2.19±0.15 | 1.93±0.14 | 0.219 |
| High-quality embryo at day two (%) | 22.13±2.31 | 27.84±2.31 | 0.081 |
| High-quality embryo at day three (%) | 40.27±2.99 | 45.29±2.94 | 0.229 |
| Blastocyst development (%) | 42.21±4.55 | 47.81±4.81 | 0.433 |
| Clinical outcome | |||
| Endometrial thickness | 11.39±2.31 | 11.01±1.84 | 0.114 |
| Implantation rate | 18.21±37.93 | 25.89±44.48 | 0.121 |
| Cycle’s cancelation rate | 9.00 | 16.00 | 0.189 |
| Pregnancy rate | 32.07 | 31.53 | 0.542 |
| Miscarriage rate | 9.52 | 5.00 | 0.519 |